Kornimate/medical-research-clean huggingface dataset:
effect of kinesiotaping on ankle stability

Conditions: Sprain and Strain of Ankle

Summary: ankles sprains are the most popular injuries in basketball players. they are traumatic injuries, which happen most of the time in specific situations, like landing on another player's foot, or during changes of direction. neuromuscular exercises are very important to improve ankle stability and reduce risks of sprains. however various external support such as ankles braces and rigid tape, are also used in order to prevent injury. the kinesiotape (kt) is a new but broadly used method in the world of athletes. created by kenzokase, in 1980, this kind of tape has a tremendous success with athletes and is today commonly used during practices and/or competitions. the main property of this tape is its elasticity, which is supposed to improve proprioception and, thus ankle stability, but these aspects have not been investigated yet.

aim: compare the effects of a kinesiotape (kt) with a sham treatment (kt put with no effects) and a control condition (absence of tape) in basketball players from the swiss national league through balance tests on an unstable surface. hypotheses: a kt positioned on the lateral side of the leg improves ankle stability in basketball players while balancing on an unstable surface. method: 30 subjects will be recruited from different basketball teams affiliated to the swiss national league. they will have to perform some postural stability tests on both unstable ("delos") and stable surfaces ("single les stance", "star excursion balance test", "cross over hop test for distance") under three different conditions. the three condition will be as followed : with a kt positioned on the lateral side of the leg, with a sham tape or without tape. the three sessions will be spaced in time (7 days of wash out). the order of the three interventions (kt, sham tape, no tape) will be randomized (cross over) to avoid the bias of learning processes. neither the subjects nor the examiner will be aware of the "tape condition" (double blind); a physiotherapist will be in charge of positioning the tape according to the tested condition. the sequence of the tests will be the same for all subjects and breaks are scheduled to avoid the effect of the fatigue. an anamnesis of all subjects will be done in order to evaluate history of injuries. at the end of each session, a visual analogical scale will be completed by the athlete to obtain a personal feeling of stability . the subject will be also asked to determine which condition was tested. expected results: the application of a kt on the lateral side of the leg improves postural stability on instable surfaces in elite basketball players. field's importance: the application of kt may reduce the risk of ankle sprains and the recurrence of sprains in a population of athletes at risk.

Eligibility criteria:
inclusion criteria: * active elite basketball players exclusion criteria: * no history of ankle sprain in the last 6 weeks * no history of any other lower limbs lesion in the last 6 weeks

Keywords: kinestiotaping basketball players effect of kinesiotaping on postural stability
identification sepsis related single nucleotide polymorphism (snp) by whole exome sequencing

Conditions: Sepsis

Summary: sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. single nucleotide polymorphism (snp) was promising genetic biomarker for sepsis patients. the present study was designed to screen several snp by whole exome sequencing which evaluate the sepsis related snp site in order to be a new target for the treatment of sepsis.

the study is a non-intervention, prospective observational study. purpose of this sudy is to screening several snps by whole exome sequencing which can be used as genetic marker for sepsis patients. we will collect whole blood samples from patients with sepsis inrespiratory intensive care unit (ricu), the emergency intensive care unit (eicu), or the department of surgery's icu 301 hospital since january 2013, and then whole exome sequencing was used to screen snps which were related to sepsis. then another 500 sepsis patients and 500 normal controls were used to validated the sequencing results.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of sepsis * patients who agree with the study exclusion criteria: * aged \<18 years; * into the group who died within 24 hours; * agranulocytosis (\<0.5 × 109 / l); * combined hiv infection.

Keywords: sepsis snp mortality
chairos study a study of mabthera/rituxan (rituximab) maintenance therapy in patients with b-cell chronic lymphocytic leukemia (cll) naive to chemotherapy

Conditions: Lymphocytic Leukemia, Chronic

Summary: this study will evaluate the efficacy and safety of intense combination treatment including mabthera/rituxan (rituximab), followed by mabthera/rituxan maintenance therapy in patients with b-cell cll who are naive to chemotherapy. the anticipated time on study treatment is 2.5 years.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * b-cell cll * no previous chemotherapy, radiotherapy, or immunotherapy exclusion criteria: * reduced organ function, or bone marrow dysfunction not due to cll * patients with a history of other malignancies within 2 years prior to study entry, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer * patients with a history of severe cardiac disease.
laser therapy versus electrosurgery for nasal telangiectasias

Conditions: Telangiectasis

Summary: the aim of this study is to compare the efficacy of various treatment options for eliminating nasal telangiectasias. the study will compare the outcome of treating nasal telangiectasias with the following; no treatment (control site), alexandrite laser, pulsed dye laser, combination pulsed dye laser and nd:yag 1064nm multiplex laser system and electrosurgery.


Eligibility criteria:
inclusion criteria: * over 18 years of age * able to give informed consent themselves * willing to return for follow up visit * 0.5 - 3 millimeter vessel size * 5 non-contiguous nasal vascular lesions exclusion criteria: * mentally handicapped * unable to understand written and oral english * incarceration * under 18 years of age * unwilling to return for follow up * pregnant women * vessels less than 0.5 millimeter caliber * less than 5 non-contiguous vessels

Keywords: nasal telangiectasis
5 years follow up of the sapien 3 valve from the directavi trial

Conditions: Coronary Syndrome; Hemodynamic Instability

Summary: a strategy of transcatheter aortic valve replacement (tavr) without balloon predilatation has shown to be feasible in routine in observational studies and in two recent randomized trial including the directavi trial. whether the initial implantation strategy may impact the long-term trans catheter heart valve (thv) performances and patient outcomes remains unknown to date. the investigators therefore aimed to evaluate the 5-years impact of the implantation strategy on thv hemodynamic performances and clinical outcomes in patients included in the directavi trial.

all patients (n=236) included in the directavi randomized trial conducted between may 2016 to may 2018 will be prospectively assessed for up to 5 years follow-up . the directavi prospective, randomized, single-center, open-label trial, demonstrated the non-inferiority of a "direct tavr" strategy using the third-generation balloon-expandable edwards sapien 3 device (edwards lifesciences, irvine, ca, usa) a systematic echographic follow-up will be performed in all patients enrolled in the directavi trial at the longest follow -up obtained after tavr between 2021 and 2022. clinical follow-up will be obtained with a brief patient clinical questionnaire or by phone by patients' cardiologist. serial echographic follow-up will be obtained by patients' cardiologist except for the latest follow-up echocardiography (primary end point) performed in the reference center at montpellier university hospital by two experienced cardiologists specialized in valvular echography to avoid inter operator variability.

Eligibility criteria:
inclusion criteria: * older than 18 years old. * patients included in the directavi trial exclusion criteria: - patients not living in france

Keywords: patients included in the directavi trial tavr hemodynamic performances long term follow up
test-and-treat for influenza in homeless shelters

Conditions: Influenza; Respiratory Viral Infection

Summary: this study is a stepped-wedge cluster-randomized trial of on-site rapid testing and treatment for influenza in homeless shelters within the seattle area to determine whether this strategy reduced the incidence of influenza in the shelter environment.

the study will be conducted over the course of two flu seasons, and all shelters will start with routine surveillance of influenza using mid-turbinate nasal swabs for sample collection and rt-pcr testing. shelters will be randomized to implement a test-and-treat strategy at different months throughout flu season, treating individuals who present ari symptoms or new or worsening cough within 2 days (48 hours). shelters will continue routine surveillance until all offer the test-and-treat strategy. eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment. individuals with 3-7 days of symptoms, or who choose not to participate in the intervention strategy, will still be eligible for participation in the routine surveillance. our primary hypothesis is that implementation of a point-of-care diagnostic and antiviral treatment intervention among sheltered individuals experiencing homelessness will reduce the incidence of influenza within this population over the course of a flu season. a process evaluation will also be conducted to explore the feasibility of point-of-care testing implementation in this population.

Eligibility criteria:
inclusion criteria: * resident for 1 or more days at a participating shelter * ≥2 ari symptoms or acute cough alone * willing to take study medication * willing to comply with all study procedures, including weekly surveillance and repeat nasal swab at day 2/3 and day 5/6/7 post-treatment * able to provide written, informed consent and/or assent exclusion criteria: * any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration * inability to consent and/or comply with study protocol * individuals who have received oseltamivir or baloxavir within past 7 days for treatment of influenza * individuals with known hypersensitivity to baloxavir marboxil or oseltamivir * individuals with chronic kidney disease

Keywords: tamiflu oseltamivir baloxavir influenza flu rapid test xofluza
stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring

Conditions: Prostate Cancer

Summary: the spark trial is testing the use of kilovoltage intrafraction monitoring in prostate cancer patients being treated with stereotactic prostate adaptive radiotherapy. the researchers expect this trial to result in better targeted prostate cancer patient outcomes with lower toxicity. the potential application of kilovoltage intrafraction monitoring to other tumour sites will pave the way for additional trials with australasian radiation oncology leading the world.

most linear accelerators used to treat cancer patients today are equipped with fixed x-ray imagers which are typically used to take images of a tumour before a patient receives radiotherapy. a new technology, known as kilovoltage intrafraction monitoring has recently emerged which allows images of a tumour to be taken in real-time while the treatment is occurring. the advantage of kilovoltage intrafraction monitoring is that it enables strategies such as patient shifting or beam shifting during treatment which could potentially improve the accuracy of the treatment and reduce the patient's side effects. in addition, due to the accuracy of kilovoltage intrafraction monitoring in targeting tumours, the number of treatment sessions this group of patients will require will be reduced to five as opposed to the 40 sessions required using more conventional treatment methods.

Eligibility criteria:
inclusion criteria: 1. histologically proven prostate adenocarcinoma 2. low or intermediate risk disease as defined by: * low risk: all of psa\<10 ng/ml, gleason grade 6 and stage t1 or t2a * intermediate risk: any or all of psa 10-20 ng/ml, gleason grade 7 or stage t2b-c * absence of high risk features (psa\>20, t3-4, n1 or m1 disease, gleason score 8-10) (psa must be within 3 months prior to enrolment) 3. ecog performance status 0-2 4. suitable for definitive external beam radiotherapy (imrt or vmat) 5. ability to have three gold fiducial markers placed in the prostate 6. six month course of androgen deprivation therapy allowed at clinician discretion. 7. available for follow up for a minimum of 2 years (up to 3 years) exclusion criteria: 1. lymph node irradiation 2. any other systemic anti-prostate cancer therapy (i.e. non-adt) both proven in the metastatic setting and investigational (e.g. docetaxel, enzalutamide) 3. artificial hip(s) (unable to visualise markers through prosthesis) 4. prostate volume \> 90 cm3 measured from the ct scan 5. patient lateral dimension \>40cm as measured at the level of the prostate from the ct scan 6. suboptimal fiducial markers placement for treatment utilising kim as assessed by a medical physicist by measuring marker positions from the ct scan 7. fiducial migration or fewer than 3 fiducials present in the ct scan
inav-based, automated coronary magnetic resonance angiography for the detection of coronary artery stenosis

Conditions: Coronary Artery Stenosis

Summary: ischaemic heart disease (ihd) is the worlds leading cause of death. ihd is often caused by a narrowing of the coronary arteries, which prevents blood from flowing to the heart muscle, causing pain and damage to the heart. if an individual has a myocardial infarction (mi), parts of the heart that are damaged cannot be repaired. therefore, it is important to identify and treat the narrowing of the arteries before an mi occurs. at present there are 2 main methods of identifying narrowing of the arteries. the first is an invasive procedure, the other using a ct scan. whilst both methods are effective, they entail risk. the invasive procedure can damage the coronary arteries, whilst the ct scan exposes patients to radiation and contrast, which can increase the risk of cancer and allergic reactions. magnetic resonance (mr) scanning is an alternative to these methods, but it has been limited in use in the past due, in part, to the high technical knowledge required to obtain images. in addition, there is a degree of subjectivity in the selection of the mid-diastolic rest period, potentially affecting consistency of results. this means it is difficult to use in a day-to-day hospital environment. however, recent technological developments using artificial intelligence mean that images can be acquired in a more automated and consistent fashion. this new scan has yet to be tested in a clinical trial. therefore, the objective of the clinical study is to test this new scan to determine its efficacy. 230 patients at 5 sites at risk of coronary artery disease, who have been referred for invasive coronary angiography, will undergo both their angiography and the new mr scan. the mr scan will then be compared to ccta for diagnostic accuracy and image quality. the investigators hypothesise that the new mr scan will have the same diagnostic accuracy as invasive coronary angiography, with no differences in interpretation of the images across the 5 different hospitals. if proven effective, this would demonstrate that mr scanning of the coronary arteries could prove a safe, clinically useful alternative to both ct scanning and invasive assessment of coronary artery narrowing. in addition, if there is no difference across different locations, it would demonstrate that these scans can be performed consistently, facilitating implementation on a healthcare-system wide basis.


Eligibility criteria:
inclusion criteria: * inclusion criteria: * ≥18 years old * subject has provided informed written consent * bmi \< 35 * sinus rhythm * stable symptom at time of inclusion * undergoing ccta within 28 days exclusion criteria: * any contraindication to cmr * previous coronary revascularisation * inability to take sublingual nitroglycerin * irregular heart rate

Keywords: coronary magnetic resonance angiography coronary artery stenosis artificial intelligence
open-label v565 target engagement study

Conditions: Ulcerative Colitis

Summary: the purpose of the study is to confirm that v565 enters inflamed tissue, binds to tnf and reduces inflammation after oral dosing to patients with ibd.

single-site, open-label study in up to 6 patients treated for up to 7 days with sigmoidoscopy and biopsies before and after treatment period to determine biological activity.

Eligibility criteria:
inclusion criteria: * established diagnosis of uc for 12 months or more * distal disease, accessible by flexible sigmoidoscopy * mild to moderate uc as defined as mayo score between 3 - 10 with mayo endoscopic sub score ≥1 exclusion criteria: * a known hypersensitivity to any of the inactive ingredients of the study treatment * a diagnosis of any ibd except uc * isolated proctitis * stool culture positive for c. difficile or other enteric infection * untreated tuberculosis (tb); positive quantiferon-tb gold test result (performed by central laboratory) * evidence of previous or present hepatitis b or c infection * known severe viral infection within six weeks prior to visit 1 * current use of topical mesalazine or anti-infectives for serious infection (or within 1 week) * anti-tnfα therapy other than the study drug * parenteral or enteral nutrition therapy * current use of any biologic agent * primary failure or secondary loss of response (lor) to use of a tnfα inhibitor * contraindication to tnfα inhibitor * clinically significant abnormal laboratory test result at screening * taken an investigational drug within 3 months or 5 half-lives (whichever is longer) prior to the first dose in this study.
lifestyle medicine for depression 2019

Conditions: Depression

Summary: this study will examine the feasibility and efficacy of lifestyle medicine for the enhancement of psychological wellness in adult. the main components of lifestyle intervention typically include physical activity, diet, relaxation/mindfulness, sleep and socialisation. these components are weaved with psychological elements such as stress management, cognitive restructuring, motivational interviewing, and goal setting strategies that are led by clinical psychologists. while lifestyle medicine has been recognised for centuries a a mean to improve physical health, the field of lifestyle medicine in the context of mental health is still in its infancy. nevertheless, there is increasing evidence demonstrating the efficacy of individual components of lifestyle medicine (e.g. diet, physical activities, and sleep) on mood and stress management. with a well-researched lifestyle medicine programme adopted from australia, the research team of the chinese university of hong kong has customised the intervention protocol to fit the chinese culture. the investigators aim to examine the effectiveness of an integration of multiple lifestyle adjustments on depression from a holistic body-mind perspective.


Eligibility criteria:
inclusion criteria: * hong kong residents aged ≥ 18 years; * cantonese language fluency; * patient health questionnaire (phq-9) score ≥ 10; and * willingness to provide informed consent and comply with the trial protocol exclusion criteria: * pregnancy; * have suicidal ideation with phq-9 item 9 score ≥ 2 (referral information to professional services will be provided to those who endorsed items on suicidal ideation); * using medication or psychotherapy for depression; * having unsafe conditions and are not recommended for physical activity or a change in diet by physicians; and * have major psychiatric, medical or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle intervention

Keywords: depression lifestyle medicine
rheoparin-coated tubing system for minimized extracorporeal circulation (mecc)

Conditions: Extracorporeal Circulation; Inflammation; Blood Coagulation; Intracranial Embolism

Summary: in this study, the investigators would like to compare a heparin-coated tubing system for minimized extracorporeal circulation (mecc) with the conventional tubing system for mecc, which does not contain heparin coating. the mecc system has been used since 14 years in the investigators' hospital as an extracorporeal system to support circulation and provide oxygen to the tissues during coronary artery bypass grafting. until today, the investigators performed more than 5000 mecc procedures in their department.

background the investigators would like to investigate a new composition of their mecc system in patients receiving coronary artery bypass surgery. normally, the mecc system induces complement system activation and coagulation cascade, which could have a negative impact on postoperative outcome. a tubing system containing heparin (rheoparin) could contribute to a better biocompatibility in terms of a diminished activation of inflammatory reactions and a reduction of cerebral embolic load, which is a regular issue during extracorporeal circulation due to formation of solid and gaseous microemboli in the tubing system. objective the aim is to investigate biocompatibility (coagulation, inflammation) and influence on cerebral embolic load of the rheoparin-coated mecc system and to compare the results with the current mecc system containing a rheoparin-free tubing system. methods patients undergoing elective coronary artery surgery are randomized to receive extracorporeal circulation using the mecc system with or without rheoparin coating. all procedures are performed according to the institutional standards.

Eligibility criteria:
inclusion criteria: * written informed consent * elective cardiac surgery * coronary artery bypass grafting exclusion criteria * re do * usage of antiplatelets, antithrombotic drugs * coagulopathy * persistent foramen ovale * infection * heparin-induced thrombocytopenia (hit)